3.30

3.77% +0.12

After Hours: 3.30

Genenta Science SpA ADR (GNTA)

Overview News Price History Discussions Forecast

Genenta Science SpA ADR stock is currently priced at $3.30, with a 24-hour trading volume of 1,686. It has seen a +3.77% increased in the last 24 hours and a +10.00% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $3.25 pivot point. If it approaches the $3.31 resistance level, significant changes may occur.

Previous Close:

$3.18

Open:

$3.34

24h Volume:

1,686

Market Cap:

$60.12M

Revenue:

Net Income/Loss:

$-12.63M

P/E Ratio:

-6.8636

EPS:

-0.4808

Net Cash Flow:

$-12.18M

1W Performance:

+6.45%

1M Performance:

+10.00%

6M Performance:

-38.89%

1Y Performance:

-45.90%

1D Range:

$3.25

$3.34

52W Range:

$2.20

$6.81

Genenta Science SpA ADR Stock (GNTA) Company Profile

Name

Genenta Science SpA ADR

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

39 02 26 43 46 81

Address

Via Olgettina No. 58, Milan

Employee

Twitter

Next Earnings Date

Latest SEC Filings

GNTA's Discussions on Twitter

Genenta Science SpA ADR Stock (GNTA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-25-22	Initiated	H.C. Wainwright	Buy
Jan-13-22	Initiated	Maxim Group	Buy

Genenta Science SpA ADR Stock (GNTA) Latest News

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

GlobeNewswire Inc.

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

GlobeNewswire Inc.

Why Urban Outfitters Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Genenta Science SpA ADR Stock (GNTA) Financials Data

Genenta Science SpA ADR (GNTA) Net Income 2024

GNTA net income (TTM) was -$12.63 million for the quarter ending December 31, 2023, a -92.19% decrease year-over-year.

Genenta Science SpA ADR (GNTA) Cash Flow 2024

GNTA recorded a free cash flow (TTM) of -$12.18 million for the quarter ending December 31, 2023, a -47.56% decrease year-over-year.

Genenta Science SpA ADR (GNTA) Earnings per Share 2024

GNTA earnings per share (TTM) was -$0.6942 for the quarter ending December 31, 2023, a -64.04% decline year-over-year.

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon and other immune-gene therapy programs for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.